<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641899</url>
  </required_header>
  <id_info>
    <org_study_id>ITCA 650-CLP-115</org_study_id>
    <nct_id>NCT02641899</nct_id>
  </id_info>
  <brief_title>Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs</brief_title>
  <official_title>A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied Drug/Drug Interaction (DDI) Probe Compounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intarcia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intarcia Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of
      ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly
      Studied DDI Probe Compounds.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acetaminophen will be use to assess the effect of ITCA 650 on the rate of gastric emptying.

      Interactions between ITCA 650 and the medications lisinopril, digoxin, atorvastatin, and
      warfarin will also be studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the last measurable concentration [AUC(0-last)]) of acetaminophen alone and in the presence of ITCA 650.</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration ([Cmax]) of acetaminophen alone and in the presence of ITCA 650</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC(0-last)) of atorvastatin, lisinopril, digoxin, R-warfarin, and S-warfarin each alone and in the presence of ITCA 650.</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of atorvastatin, lisinopril, digoxin, R-warfarin, and S-warfarin each alone and in the presence of ITCA 650.</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (tmax) of acetaminophen</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of atorvastatin, lisinopril, digoxin, R warfarin, and S-warfarin</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-last) of orthohydroxy-atorvastatin and parahydroxy-atorvastatin</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of orthohydroxy-atorvastatin and parahydroxy-atorvastatin</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum effect (Emax)from time zero to the last measurable concentration (AUEC(0-last)) of international normalized ratio (INR) of warfarin.</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ITCA 650, 20 mcg/d and 60 mcg/d</measure>
    <time_frame>within 8 hours after placement of ITCA 650</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs) including any events local to the placement site, clinical laboratory measurements, ECGs, vital signs and physical examinations.</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of orthohydroxy-atorvastatin and parahydroxy-atorvastatin</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of ITCA 650, 20 mcg/d and 60 mcg/d</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ITCA 650, 20 mcg/d and 60 mcg/d</measure>
    <time_frame>time zero to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmin of ITCA 650, 20 mcg/d and 60 mcg/d</measure>
    <time_frame>zero to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum effect (tEmax)from time zero to the last measurable concentration (AUEC(0-last)) of international normalized ratio (INR) of warfarin.</measure>
    <time_frame>zero to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the effect-time curve from time zero to the last measurable concentration (AUEC(0-last)) of international normalized ratio (INR) of warfarin.</measure>
    <time_frame>zero to 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Experimental Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ITCA 650 20/60 mcg/day Acetaminophen 1000 mg Atorvastatin 40 mg Lisinopril 20 mg Warfarin 25 mg Digoxin 0.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ITCA 650 20/60 mcg/day</intervention_name>
    <description>ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.</description>
    <arm_group_label>Experimental Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Oral acetaminophen 1000 mg on Day 1 and Day 27</description>
    <arm_group_label>Experimental Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Oral atorvastatin 40 mg on Day 2 and Day 28</description>
    <arm_group_label>Experimental Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>Oral lisinopril 20 mg on Day 2 and Day 28</description>
    <arm_group_label>Experimental Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Oral warfarin 25 mg on Day 2 and Day 28</description>
    <arm_group_label>Experimental Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Oral digoxin 0.5 mg on Day 2 and Day 28</description>
    <arm_group_label>Experimental Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) between 19 to 32 kg/m2.

          -  Glycosylated hemoglobin A1c (HbA1c )&lt;6.5%.

          -  Normal renal function (eGFR ≥80 mL/min/1.73 m2).

          -  Women of child bearing potential - use of an additional adequate method of
             contraception during the study and until 1 additional menstrual cycle following the
             end-of-study (EOS) visit. Adequate methods of contraception for women of child bearing
             potential (WOCBP) include: mechanical products (ie, intrauterine device [IUD]—copper
             IUD); or barrier methods (eg, diaphragm, condoms, cervical cap) with spermicide.

        Exclusion Criteria:

          -  History of type 1 or type 2 diabetes.

          -  History or evidence of myocardial infarction, coronary revascularization (coronary
             artery bypass grafting or percutaneous coronary intervention), unstable angina, or
             cerebrovascular accident or stroke.

          -  History of uncontrolled hypertension.

          -  History or evidence of acute or chronic pancreatitis.

          -  History of liver disease.

          -  History of medullary thyroid cancer or a personal or family history of multiple
             endocrine neoplasia type 2.

          -  Poor thyroid, liver, or renal function.

          -  Weight loss surgery or requires weight loss medications.

          -  History of malignancy (not including basal or squamous cell carcinoma of the skin with
             past 5 years). (Subjects who have been disease free for 5 years may be included.)

          -  History of active alcohol or substance abuse.

          -  Weekly consumption of more than 7 alcoholic beverages for females and 14 alcoholic
             beverages for males.

          -  Excessive in xanthine consumption (more than 5 cups of coffee or equivalent per day).

          -  Treatment with medications that affect GI motility.

          -  Any condition that would affect drug transit time or absorption (eg, gastrointestinal
             bypass surgery, partial or total gastrectomy, small bowel resection, chronic diarrhea,
             vagotomy, chronic gastroesophageal reflux disease, malabsorption, colostomy, Crohn's
             disease, ulcerative colitis, or celiac sprue).

          -  History of hypersensitivity to exenatide.

          -  Contraindications or warnings according to the specific label(s) for acetaminophen,
             atorvastatin, lisinopril, digoxin or warfarin therapy.

          -  Women that are pregnant, lactating, or planning to become pregnant.

          -  Concurrent use of anticoagulants, including daily low dose aspirin (81 mg).

          -  History of or positive results on screening tests for hepatitis B and/or hepatitis C
             and/or human immunodeficiency virus (HIV).

          -  Planned in-patient surgery, dental procedure, or hospitalization during the study.

          -  Prior or current treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist
             (eg, Bydureon™, Byetta®, Victoza®, Tanzeum® or exogenous native GLP-1) or prior
             participation in an ITCA 650 clinical trial.

          -  Use or intended use of any drug or other product that inhibits or induces cytochrome
             P450 (CYP)1A2, CYP2C9, CYP2C19, or CYP3A4 within 14 days prior to the first dose of
             warfarin or ITCA650 or during the conduct of the study.

          -  History of thrombophlebitis, thromboembolic disorders, or deep vein thrombophlebitis.

          -  Fasting triglycerides above upper limit of normal at Screening.

          -  Any gastrointestinal complaints within 7 days prior to first dosing.

          -  Taking drugs or natural herbal supplements (such as albuterol, antacids, and St.
             John's Wort) with known interactions with atorvastatin, lisinopril, digoxin, or
             warfarin from within 7 days prior to Day 1 until EOS

          -  Consumed or unwilling to refrain from grapefruit, cranberries, grapefruit- or
             cranberry-containing products, or Seville oranges from within 7 days prior to Day 1
             until EOS.

          -  Chronic use of analgesics, pain medication, or non-steroidal anti-inflammatory agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quintiles</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult</keyword>
  <keyword>Male</keyword>
  <keyword>Female</keyword>
  <keyword>Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

